Integrated Diagnostics (IDHC) Share Price, News & Analysis

Company Overview

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of clinical pathology and radiology tests to patients in Egypt, Jordan, Nigeria, Sudan, and Saudi Arabia. The Group’s core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar Sudan (both in Sudan), and Biolab KSA (Saudi Arabia). With over 40 years of experience, a long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 3,000 diagnostics tests. From its base of 601 branches as of 31 December 2023, IDH served over 8.5 million patients and performed more than 36.1 million tests in 2023. IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group targets expansion in appealing markets, including acquisitions in the Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity (i) whose shares are admitted to the equity shares (transition) category (previously, the standard listing segment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange (ticker: IDHC) since May 2015.

Key Stats

• Today's Range: 0.33 to 0.36
• 50-Day Range: 0.31 to 0.40
• 52-Week Range: 0.28 to 0.54
• Volume: 1,119 shs
• Average Volume: 173,853 shs
• Market Capitalization: £10.60 billion
• P/E Ratio: 13.38
• Dividend Yield: 2,777.78%
• Price Target: N/A
• Consensus Rating: N/A

IDHC Stock Analysis - Frequently Asked Questions

How have IDHC shares performed this year?

Integrated Diagnostics' stock was trading at GBX 0.45 at the beginning of 2025. Since then, IDHC shares have decreased by 19.8% and is now trading at GBX 0.36.
View the best growth stocks for 2025 here.

How do I buy shares of Integrated Diagnostics?

Shares of IDHC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Integrated Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Integrated Diagnostics investors own include Georgia Healthcare Group PLC (GHG.L) (GHG), VEON (VEON), Pao Tmk (TMKXY) and M.P. Evans Group (MPE).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:IDHC
• CIK: N/A
• Web: www.idhcorp.com
• Phone: +44-1534-847000
• Fax: N/A
• Employees: 6,692
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX 0.03
• Trailing P/E Ratio: 13.38
• Forward P/E Ratio: 0.26
• P/E Growth: 7.65
• Net Income: £4.01 trillion
• Net Margins: 17.21%
• Pretax Margin: N/A
• Return on Equity: 30.45%
• Return on Assets: 9.69%

Debt

• Debt-to-Equity Ratio: 45.72
• Current Ratio: 1.59
• Quick Ratio: 0.75

Sales & Book Value

• Annual Sales: £23.29 trillion
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX 591.97 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 2,943,148,899,320
• Free Float: N/A
• Market Cap: £10.60 billion
• Optionable: Not Optionable
• Beta: 0.59